FDA Removes from Market Unapproved Cough and Cold Prescription Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Removes from Market Unapproved Cough and Cold Prescription Products


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA announced on Mar. 2, 2011, that it is taking action against companies that manufacture, distribute, or market certain unapproved prescription oral cough, cold, and allergy products, according to an agency release and press briefing.

FDA’s Office of Compliance Director Deborah M. Author explained in a press briefing that the legal requirements for evaluating and approving prescription drugs have changed over the past century, including the enactment of the Food, Drug, & Cosmetic Act, and that, still, many drugs have remained on or entered the market illegally.

This class of drugs is of particular concern because many of these products are labeled as “timed release,” which are complicated to manufacture. It is important, said Author, that FDA review these types of drugs to ensure that the release of the active ingredient is occurring at the right time and in the right dosage. This class of drugs is also important because many of the products are labeled for children age 2 and under. In 2008, the agency called for the relabeling of over-the-counter cough, cold, and allergy medications for children under age 2 because of potential serious side effects.

According to the agency press release, “Unapproved prescription cough, cold, and allergy drug products have not been evaluated by the FDA for safety, effectiveness, and quality. People may be at greater risk when using these products than when using FDA-approved prescription drugs or drugs that are appropriately marketed over-the-counter.” 

The action, which is part of FDA’s 2006 unapproved drugs initiative, calls for companies that have previously listed products subject to FDA’s action to stop manufacturing the products within 90 days and to stop shipping the products within 180 days.  In addition, companies that have not previously listed products subject to today’s action with FDA are asked to stop manufacturing and shipping their products immediately. The overall initiative has prompted the removal of 550 unapproved products from the market in the past five years. This latest action affects 500 unapproved prescription products.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here